Summary
Intravenously administered ciprofloxacin is particially secreted into the intestinal lumen and thereby eliminates fecal Enterobacteriaceae. Sucralfate inhibits the antimicrobial activity of ciprofloxacin by chelate binding. In a prospective study, we investigated the impact of intravenous ciprofloxacin on the intestinal microflora during oral administration of sucralfate. A total of 45 stool specimens were analyzed in 20 hospitalized patients who were treated with 200 mg of ciprofloxacin i.v. bid. Ten patients concomitantly received 1 g sucralfate p.o. tid (group A). After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 ± 158.7 μg/g in patients of group A and 108.7 ± 76.9 μg/g in patients without concurrent sucralfate (group B). There was no significant difference in mean fecal ciprofloxacin levels between both groups (Wilcoxon's test). Enterobacteriaceae were below the threshold of detection (102 cfu/g) in all patients of group B after 3 days of treatment whereas small numbers were found in only 2 samples of patients of group A (104 cfu/g). Intravenous ciprofloxacin eliminates or largely reduces intestinal Enterobacteriaceae irrespective of concurrent administration of sucralfate.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: November 13, 1998 · Accepted: July 20, 1999
Rights and permissions
About this article
Cite this article
Krueger, W., Ruckdeschel, G. & Unertl, K. Elimination of Fecal Enterobacteriaceae by Intravenous Ciprofloxacin Is not Inhibited by Concomitant Sucralfate – a Microbiological and Pharmacokinetic Study in Patients. Infection 27, 335–340 (1999). https://doi.org/10.1007/s150100050039
Issue Date:
DOI: https://doi.org/10.1007/s150100050039